NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kali Therapeutics

Kali Therapeutics

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://www.kalitherapeutics.com/

Last Round

Strategic

Mar 23, 2026

Total Funding Raised

$180M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kali Therapeutics is a biotechnology company that develops trispecific T-cell engager therapies designed to reset the immune system for the treatment of autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biologicst-cell engagersTCEautoimmune diseaseb-cell depletioncd3-maskingprotein engineeringtrispecific antibodybispecific antibodydrug discovery platformimmune-resettingbiotech licensingnext-gen biologicscytokine release syndromeCRS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kali Therapeutics Comparables

Compare Kali Therapeutics with similar companies based on industry and business-model similarity.

Kali Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oblenio Bio
91%
Boulevard Bio
89%
Excalipoint Therapeutics
82%

Kali Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 23, 2026

Key People

Founding team and executive leadership

Min Bao

CMO Cofounder

Founding Team

Weihao X.

Founder and CEO

Founding Team

Kali Therapeutics Investors

Notable investors and investment history

Kali Therapeutics investors
InvestorRounds
LYFE CapitalSeed, Early Funding, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased from 0 to 7, representing 88% of headcount.

Kali Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kali Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kali Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range8
Year Founded2024
Last FundingMar 23, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.